A Pilot Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), in Patients with Surgically Accessible Recurrent / Progressive Glioblastoma
The goal of this clinical research study is to learn if pembrolizumab (MK-3475) can help to control glioblastoma that has returned after treatment. The safety of this drug will also be studied. Participants in this study will also be having surgery for the brain tumor as part of standard care.
Treatment Location: N/A
IRB Review and Approval Date: 03/29/2017
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: